NCT01861314View on ClinicalTrials.gov

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 3, 2013

Primary Completion Date

November 6, 2015

Study Completion Date

March 19, 2026

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
Interventions
DRUG

Bortezomib

Given SC

DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH